Syntara

Syntara (ASX:SNT) is a clinical stage drug developer focusing on diseases associated with fibrosis and inflammation. The company, founded in 1998, specializes in targeting extracellular matrix dysfunction using its expertise in amine oxidase chemistry. Its lead candidate SNT-5505 has received FDA Orphan Drug Designation and clearance under an Investigational New Drug Application for the treatment of myelofibrosis, a bone marrow cancer causing scar tissue buildup. Syntara is currently managing three phase 2 clinical studies and evaluating the potential for two more phase 1c/2 studies by 2024.

The company is also involved in developing oral and topical pan-LOX inhibitors for scar prevention and modification, and collaborating with Professor Fiona Wood and the University of Western Australia. Additionally, Syntara is studying SNT-4728 in collaboration with Parkinson’s UK as an SSAO/MAOB inhibitor for the treatment of sleep disorders and neurodegenerative diseases like Parkinson’s.

Further, Syntara has developed respiratory products, Bronchitol® and Aridol®, available in global markets for which it receives royalties. Its pipeline includes drug candidates targeting kidney fibrosis, NASH, pulmonary fibrosis, and cardiac fibrosis. The company received a $1.39M Post-IPO Equity investment on 18 June 2009.